Screener
ArriVent BioPharma, Inc. AVBP Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by ArriVent BioPharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: ArriVent BioPharma, Inc.’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:08 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-058650
| Line item | Three Months Ended / March 31, 2026 | Three Months Ended / March 31, 2025 |
|---|---|---|
| Research and development | $37,617 | $61,289 |
| General and administrative | 8,494 | 5,483 |
| Total operating expenses | 46,111 | 66,772 |
| Operating loss | (46,111) | (66,772) |
| Interest and investment income | 2,791 | 2,385 |
| Net loss | (43,320) | (64,387) |
| Unrealized gain (loss) on marketable securities | (284) | 194 |
| Total other comprehensive gain (loss) | (284) | 194 |
Item 1. Condensed Financial Statements (Unaudited):
FAQ
- What is ArriVent BioPharma, Inc.'s operating income?
- ArriVent BioPharma, Inc. (AVBP) reported operating income of -$46.11M in Q1 2026.
- How has ArriVent BioPharma, Inc.'s operating income changed year-over-year?
- ArriVent BioPharma, Inc.'s operating income increased by 30.9% year-over-year, from -$66.77M to -$46.11M.
- What is the long-term trend for ArriVent BioPharma, Inc.'s operating income?
- Over 2 years (2023 to 2025), ArriVent BioPharma, Inc.'s operating income has grown at a 54.3% compound annual growth rate (CAGR), from -$74.59M to -$177.53M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about ArriVent BioPharma, Inc.'s operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude